—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Virbac SA (VIRP.PA) — the peer cohort

As of 2026-11-10 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Virbac SA ranks 7 of 9 in its cohort on the Closelooknet composite (50/100) — the cohort is led by Eli Lilly and Company at 64/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
VIRP.PA Virbac SA 50 61 52 55 info 7.8%
LLY Eli Lilly and Company 64 91 90 22 bull 2.8%
ORNAV.HE Orion Oyj A 63 94 84 29 ok 1.4%
ORNBV.HE Orion Oyj B 63 94 84 29 ok 1.4%
SAN.PA Sanofi SA 63 75 69 63 bull 0.7%
AZN.L AstraZeneca PLC 55 60 75 44 info 10.2%
GSK GSK plc 55 54 78 54 info 14.8%
EL.PA EssilorLuxottica S. A. 47 46 48 48 watch 39.7%
ABVX.PA Abivax SA 38 18 53 56 warn 42.2%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-10

Quick answers

Who are Virbac SA's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Eli Lilly and Company (LLY), Orion Oyj A (ORNAV.HE), Orion Oyj B (ORNBV.HE), Sanofi SA (SAN.PA), AstraZeneca PLC (AZN.L), GSK plc (GSK), EssilorLuxottica S. A. (EL.PA), Abivax SA (ABVX.PA), as of 2026-11-10.

How does VIRP.PA score against its peers?

Virbac SA's composite reads 50/100, ranking 7 of 9 in its cohort as of 2026-11-10; the cohort's highest composite is Eli Lilly and Company at 64/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.